KEROS THERAPEUTICS INC
NASDAQ: KROS (Keros Therapeutics, Inc.)
Kemas kini terakhir: 56 minit lalu11.73
0.25 (2.18%)
| Penutupan Terdahulu | 11.48 |
| Jumlah Dagangan | 189,816 |
| Harga / Pendapatan (P/E Ke hadapan) | 48.78 |
| Harga / Jualan (P/S) | 20.19 |
| Harga / Buku (P/B) | 0.840 |
| Julat 52 Minggu |
| Margin Keuntungan | 1.96% |
| Margin Operasi (TTM) | 71.97% |
| EPS Cair (TTM) | -0.170 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 254,413.31% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.53% |
| Nisbah Semasa (MRQ) | 19.29 |
| Aliran Tunai Operasi (OCF TTM) | 44.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 30.29 M |
| Pulangan Atas Aset (ROA TTM) | -1.01% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Keros Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.83 |
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.31% |
| % Dimiliki oleh Institusi | 109.35% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nantahala Capital Management, Llc | 30 Jun 2026 | 1,410,419 |
| Orbimed Advisors Llc | 30 Jun 2026 | 759,155 |
| Federated Hermes, Inc. | 30 Jun 2026 | 700,427 |
| Mackenzie Financial Corp | 30 Jun 2026 | 628,438 |
| Madison Avenue Partners, Lp | 30 Jun 2026 | 626,583 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 605,445 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |